129 related articles for article (PubMed ID: 32889748)
41. Bone Morphogenetic Protein-8B Expression is Induced in Steatotic Hepatocytes and Promotes Hepatic Steatosis and Inflammation In Vitro.
Mahli A; Seitz T; Beckröge T; Freese K; Thasler WE; Benkert M; Dietrich P; Weiskirchen R; Bosserhoff A; Hellerbrand C
Cells; 2019 May; 8(5):. PubMed ID: 31096638
[TBL] [Abstract][Full Text] [Related]
42. Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD.
Liang J; Liu Y; Liu J; Li Z; Fan Q; Jiang Z; Yan F; Wang Z; Huang P; Feng N
J Nanobiotechnology; 2018 Sep; 16(1):64. PubMed ID: 30176941
[TBL] [Abstract][Full Text] [Related]
43. Suppression of miR-30a-3p Attenuates Hepatic Steatosis in Non-alcoholic Fatty Liver Disease.
Wang DR; Wang B; Yang M; Liu ZL; Sun J; Wang Y; Sun H; Xie LJ
Biochem Genet; 2020 Oct; 58(5):691-704. PubMed ID: 32419060
[TBL] [Abstract][Full Text] [Related]
44. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease.
Xi Y; Li H
Biomed Pharmacother; 2020 Jan; 121():109609. PubMed ID: 31731192
[TBL] [Abstract][Full Text] [Related]
45. Suppression of high-fat diet-induced obesity-associated liver mitochondrial dysfunction by docosahexaenoic acid and hydroxytyrosol co-administration.
Ortiz M; Soto-Alarcón SA; Orellana P; Espinosa A; Campos C; López-Arana S; Rincón MA; Illesca P; Valenzuela R; Videla LA
Dig Liver Dis; 2020 Aug; 52(8):895-904. PubMed ID: 32620521
[TBL] [Abstract][Full Text] [Related]
46. Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications.
Sotiropoulou M; Katsaros I; Vailas M; Lidoriki I; Papatheodoridis GV; Kostomitsopoulos NG; Valsami G; Tsaroucha A; Schizas D
Saudi J Gastroenterol; 2021; 27(6):319-330. PubMed ID: 34810376
[TBL] [Abstract][Full Text] [Related]
47. SGL 121 Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism Through AMPK Signaling Pathway.
Kim DE; Chang BY; Jeon BM; Baek JI; Kim SC; Kim SY
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630596
[TBL] [Abstract][Full Text] [Related]
48. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis.
Kim JY; Park KJ; Hwang JY; Kim GH; Lee D; Lee YJ; Song EH; Yoo MG; Kim BJ; Suh YH; Roh GS; Gao B; Kim W; Kim WH
J Hepatol; 2017 Aug; 67(2):349-359. PubMed ID: 28365312
[TBL] [Abstract][Full Text] [Related]
49. Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress.
Jiang Y; Chen L; Wang H; Narisi B; Chen B
J Ethnopharmacol; 2015 Dec; 176():499-507. PubMed ID: 26571089
[TBL] [Abstract][Full Text] [Related]
50. The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease.
Teng W; Zhao L; Yang S; Zhang C; Liu M; Luo J; Jin J; Zhang M; Bao C; Li D; Xiong W; Li Y; Ren F
J Control Release; 2019 Aug; 307():139-149. PubMed ID: 31233775
[TBL] [Abstract][Full Text] [Related]
51. Quercetin ameliorates HFD-induced NAFLD by promoting hepatic VLDL assembly and lipophagy via the IRE1a/XBP1s pathway.
Zhu X; Xiong T; Liu P; Guo X; Xiao L; Zhou F; Tang Y; Yao P
Food Chem Toxicol; 2018 Apr; 114():52-60. PubMed ID: 29438776
[TBL] [Abstract][Full Text] [Related]
52. Hesperetin ameliorates hepatic oxidative stress and inflammation
Li J; Wang T; Liu P; Yang F; Wang X; Zheng W; Sun W
Food Funct; 2021 May; 12(9):3898-3918. PubMed ID: 33977953
[TBL] [Abstract][Full Text] [Related]
53. LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).
Soares e Silva AK; de Oliveira Cipriano Torres D; dos Santos Gomes FO; dos Santos Silva B; Lima Ribeiro E; Costa Oliveira A; dos Santos LA; de Lima Mdo C; Pitta Ida R; Peixoto CA
PLoS One; 2015; 10(4):e0123787. PubMed ID: 25875942
[TBL] [Abstract][Full Text] [Related]
54. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
Lin Y; Ding D; Huang Q; Liu Q; Lu H; Lu Y; Chi Y; Sun X; Ye G; Zhu H; Wei J; Dong S
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):869-882. PubMed ID: 28483554
[TBL] [Abstract][Full Text] [Related]
55. Curcumin Ameliorates Nonalcoholic Fatty Liver Disease through Inhibition of
Lee DE; Lee SJ; Kim SJ; Lee HS; Kwon OS
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31717261
[TBL] [Abstract][Full Text] [Related]
56. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
[TBL] [Abstract][Full Text] [Related]
57. Fatty Acids and Effects on In Vitro and In Vivo Models of Liver Steatosis.
Vergani L
Curr Med Chem; 2019; 26(19):3439-3456. PubMed ID: 28521680
[TBL] [Abstract][Full Text] [Related]
58. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Lee C; Kim J; Jung Y
Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
[TBL] [Abstract][Full Text] [Related]
59. Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis.
Yang RX; Pan Q; Liu XL; Zhou D; Xin FZ; Zhao ZH; Zhang RN; Zeng J; Qiao L; Hu CX; Xu GW; Fan JG
Lipids Health Dis; 2019 Oct; 18(1):179. PubMed ID: 31639005
[TBL] [Abstract][Full Text] [Related]
60. Angiotensin-(1-7), the product of ACE2 ameliorates NAFLD by acting through its receptor Mas to regulate hepatic mitochondrial function and glycolipid metabolism.
Song LN; Liu JY; Shi TT; Zhang YC; Xin Z; Cao X; Yang JK
FASEB J; 2020 Dec; 34(12):16291-16306. PubMed ID: 33078906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
